SG
SNDX icon

Stonnington Group’s Syndax Pharmaceuticals SNDX Stock Holding History

Stonnington Group’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		$222K Buy
+11,000
New +$274K 0.06% 225

Other funds holding SNDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Stonnington Group's SNDX Position: Q1 2023 in Review

Stonnington Group opened a new position in Syndax Pharmaceuticals (SNDX) in Q1 2023: 11,000 shares worth $222K. The stake represents 0.06% of the portfolio and ranks #225 among its holdings.

163 funds tracked by Wall St. Rank hold SNDX as of Q1 2023.

  • Stonnington Group held 11,000 shares of Syndax Pharmaceuticals worth $222K as of Q1 2023.
  • Syndax Pharmaceuticals was a new Stonnington Group position in Q1 2023.
  • Syndax Pharmaceuticals made up 0.06% of Stonnington Group's portfolio in Q1 2023, its #225 holding.
  • 163 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q1 2023.

Based on Stonnington Group's 13F filing for Q1 2023, filed 14 Apr 2023.